Pilocarpine

First marketed in 1921

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C11H16N2O2
Molecular Weight	208.2569
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O

InChI

InChIKey=QCHFTSOMWOSFHM-WPRPVWTQSA-N

InChI=1S/C11H16N2O2/c1-3-10-8(6-15-11(10)14)4-9-5-12-7-13(9)2/h5,7-8,10H,3-4,6H2,1-2H3/t8-,10-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200890s001lbl.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf

Pilocarpine is an alkaloid extracted from plants of the genus Pilocarpus. The drug stimulates the muscarinic receptors (especially M3, which is expressed in smooth muscles and glands) and thus induces salivation, hypertension and water intake. Pilocarpine was appoved by FDA for the alleviation of symptoms of xerostomia in patients who have undergone radiation therapy to their head and neck cancer and in patients with Sjogren's Syndrome. Ophthalmic solution of the drug is prescribed for the treatment of glaucoma, ocular hypertension, postoperative elevated intraocular pressure, etc.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Muscarinic acetylcholine receptor M3 160 Target ID: P20309 Gene ID: 1131.0 Gene Symbol: CHRM3 Target Organism: Homo sapiens (Human) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200890s001lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/11392632	Agonist 2752

Conditions

Condition	Modality	Highest Phase	Product
Head and neck cancer 50 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	Secondary	Approved 8583	SALAGEN Approved Use SALAGEN Tablets are indicated for 1) the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck; and 2) the treatment of symptoms of dry mouth in patients with Sjogren's syndrome. Launch Date 1994
Sjogren's syndrome 8 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	Palliative	Approved 8583	SALAGEN Approved Use SALAGEN Tablets are indicated for 1) the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck; and 2) the treatment of symptoms of dry mouth in patients with Sjogren's syndrome. Launch Date 1994
Open-angle glaucoma 53 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200890s001lbl.pdf	Primary	Approved 8583	ISOPTO CARPINE Approved Use Isopto Carpine is a muscarinic cholinergic agonist indicated for (1) the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; (2) the management of acute angle-closure glaucoma; (3) the prevention of postoperative elevated IOP associated with laser surgery; (4) the induction of miosis. Launch Date 2010
Ocular hypertension 52 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200890s001lbl.pdf	Primary	Approved 8583	ISOPTO CARPINE Approved Use Isopto Carpine is a muscarinic cholinergic agonist indicated for (1) the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; (2) the management of acute angle-closure glaucoma; (3) the prevention of postoperative elevated IOP associated with laser surgery; (4) the induction of miosis. Launch Date 2010
Acute angle-closure glaucoma 3 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200890s001lbl.pdf	Primary	Approved 8583	ISOPTO CARPINE Approved Use Isopto Carpine is a muscarinic cholinergic agonist indicated for (1) the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; (2) the management of acute angle-closure glaucoma; (3) the prevention of postoperative elevated IOP associated with laser surgery; (4) the induction of miosis. Launch Date 2010

C_max

Value	Dose	Co-administered	Analyte	Population
15 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	5 mg 3 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:		PILOCARPINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
33 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	5 mg 3 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:		PILOCARPINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
0.76 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	5 mg 3 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:		PILOCARPINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
100% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	5 mg 3 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:		PILOCARPINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
2 % 4 times / day multiple, ophthalmic Recommended Dose: 2 %, 4 times / day Route: ophthalmic Route: multiple Dose: 2 %, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200890s000MedR.pdf	unhealthy, 44-75 years Health Status: unhealthy Age Group: 44-75 years Sex: M Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200890s000MedR.pdf	Disc. AE: Vision blurred... AEs leading to discontinuation/dose reduction: Vision blurred (moderate, 2 patients) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200890s000MedR.pdf
20 mg single, oral Overdose Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15093850	unhealthy, 46 years Health Status: unhealthy Age Group: 46 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/15093850	Other AEs: Increased salivation, Lacrimation... Other AEs: Increased salivation (1 patient) Lacrimation (1 patient) Vomiting (1 patient) Anxiety (1 patient) Tremor (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/15093850
100 mg single, oral Overdose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf
1.54 % 3 times / day multiple, topical Recommended Dose: 1.54 %, 3 times / day Route: topical Route: multiple Dose: 1.54 %, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32248594/	unhealthy Health Status: unhealthy Sources: https://pubmed.ncbi.nlm.nih.gov/32248594/	Sources: https://pubmed.ncbi.nlm.nih.gov/32248594/

AEs

AE	Significance	Dose	Population
Vision blurred	moderate, 2 patients Disc. AE	2 % 4 times / day multiple, ophthalmic Recommended Dose: 2 %, 4 times / day Route: ophthalmic Route: multiple Dose: 2 %, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200890s000MedR.pdf	unhealthy, 44-75 years Health Status: unhealthy Age Group: 44-75 years Sex: M Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200890s000MedR.pdf
Anxiety	1 patient	20 mg single, oral Overdose Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15093850	unhealthy, 46 years Health Status: unhealthy Age Group: 46 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/15093850
Increased salivation	1 patient	20 mg single, oral Overdose Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15093850	unhealthy, 46 years Health Status: unhealthy Age Group: 46 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/15093850
Lacrimation	1 patient	20 mg single, oral Overdose Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15093850	unhealthy, 46 years Health Status: unhealthy Age Group: 46 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/15093850
Tremor	1 patient	20 mg single, oral Overdose Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15093850	unhealthy, 46 years Health Status: unhealthy Age Group: 46 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/15093850
Vomiting	1 patient	20 mg single, oral Overdose Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15093850	unhealthy, 46 years Health Status: unhealthy Age Group: 46 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/15093850

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946	substrate 1193	substrate 1388

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2A6 879 CYP3A 227 CYP2D1 6	esterase 74 CYP2A6 626 CYP1A2 1197 CYP2C19 1119 CYP2E1 729 BCRP 697

Drug as perpetrator

Target	Modality	Activity
CYP3A 317	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1510190/pdf/brjpharm00164-0104.pdf#page=3 Page: 3.0	moderate
CYP2A6 911	inhibitor 4027 Sources: https://www.fda.gov/media/79033/download#page=3 Page: 3.0	yes [Ki 1 uM]
CYP2D1 8	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3572744/	yes [Ki 360 uM]

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP1A2 1197	substrate 4014 Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0	weak	unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0
CYP2C19 1119	substrate 4014 Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0	weak	unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0
CYP2C9 1193	substrate 4014 Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0	weak	unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0
CYP2D6 1388	substrate 4014 Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0	weak	unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0
CYP2E1 729	substrate 4014 Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0	weak	unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0
CYP3A4 1946	substrate 4014 Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0	weak	unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0
BCRP 697	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/25755207/	yes
esterase 74	substrate 4014 Sources: https://www.fda.gov/media/79033/download#page=3 Page: 3.0	yes
CYP2A6 626	substrate 4014 Sources: https://www.fda.gov/media/79033/download#page=3 Page: 3.0	yes	unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=3 Page: 3.0

Sourcing

Vendor/Aggregator	ID	URL
AA Blocks	AA00GRLD	https://www.aablocks.com/goods/Goods/detail?id=AA00GRLD
abcr GmbH	AB167837	http://www.abcr.com/shop/en/AB167837
Acorn PharmaTech	ACN-035822	http://www.acornpharmatech.com/
Alfa Chemistry	AP92137	https://reagents.alfa-chemistry.com/product/pilocarpine-cas-92-13-7-18590.html
Alichem	69004656	http://www.alichem.com/en/products/92-13-7.html
Aurora Fine Chemicals LLC	A18.030.974	http://online.aurorafinechemicals.com/info?ID=A18.030.974
ChemMol	49426222	http://www.chemmol.com/chemmol/49426222.html
ChemMol	99173770	http://www.chemmol.com/chemmol/99173770.html
Chemspace	CSSB00016990803	https://chem-space.com/CSSB00016990803
Hairui	HR101326	http://www.hairuichem.com/en/product/54-71-7.html
Hairui	HR142167	http://www.hairuichem.com/en/product/92-13-7.html
Lab Network	LN00331142	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00331142
LGC Standards	DRE-A16208380AL-100	https://www.lgcstandards.com/US/en/p/DRE-A16208380AL-100
LGC Standards	DRE-C16208380	https://www.lgcstandards.com/US/en/p/DRE-C16208380
mcule	MCULE-2634151840	https://mcule.com/MCULE-2634151840/
MolPort	MolPort-002-512-506	https://www.molport.com/shop/molecule-link/MolPort-002-512-506
OChem	12013	http://www.ocheminc.com/index.php?act=psearch&pid=092P137
R&D Chemicals	1835	http://www.rdchemicals.com/chemicals.php?mode=details&mol_id=8154
Smolecule	S539680	http://www.smolecule.com/products/s539680
Smolecule	S772644	https://www.smolecule.com/products/s772644
THE BioTek	bt-278347	https://www.thebiotek.com/product/inhibitors/bt-278347
THE BioTek	bt-308560	https://www.thebiotek.com/product/others/bt-308560

PubMed

Title	Date	PubMed
The effect of pilocarpine on salivary constituents in patients with chronic graft-versus-host disease.	2001-08	11389860
Defective fluid secretion and NaCl absorption in the parotid glands of Na+/H+ exchanger-deficient mice.	2001-07-20	11358967
Reliable measurement of mouse intraocular pressure by a servo-null micropipette system.	2001-07	11431452
Prophylactic effects of pilocarpine hydrochloride on xerostomia models induced by X-ray irradiation in rats.	2001-07	11422222
Poly(2-hydroxyethyl methacrylate) film as a drug delivery system for pilocarpine.	2001-07	11396879
Agonistic behavior in groups of limbic epileptic male rats: pattern of brain damage and moderating effects from normal rats.	2001-06-29	11423076
Salivary acinar cells from aquaporin 5-deficient mice have decreased membrane water permeability and altered cell volume regulation.	2001-06-29	11290736
Evaluation of spontaneous contamination of ocular medications.	2001-06-16	11399868
Long-term alteration of calcium homeostatic mechanisms in the pilocarpine model of temporal lobe epilepsy.	2001-06-08	11382382
Acupuncture for pilocarpine-resistant xerostomia following radiotherapy for head and neck malignancies.	2001-06-01	11380221
Modulators with convergent cellular actions elicit distinct circuit outputs.	2001-06-01	11356892
Activity-induced expression of common reference genes in individual cns neurons.	2001-06	11406652
Salivary scintigraphy for assessing the protective effect of pilocarpine in head and neck irradiated tumours.	2001-06	11403176
Potential mechanism for the additivity of pilocarpine and latanoprost.	2001-06	11384567
Behavioral and electroencephalographic analysis of seizures induced by intrahippocampal injection of granulitoxin, a neurotoxic peptide from the sea anemone Bunodosoma granulifera.	2001-06	11378671
Loss of vesicular zinc and appearance of perikaryal zinc after seizures induced by pilocarpine.	2001-05-25	11388441
Status epilepticus causes necrotic damage in the mediodorsal nucleus of the thalamus in immature rats.	2001-05-15	11331388
Calculation of the uncertainty in complication probability for various dose-response models, applied to the parotid gland.	2001-05-01	11316558
Amino acid derivatives with anticonvulsant activity.	2001-05	11383620
Function of pulmonary neuronal M(2) muscarinic receptors in stable chronic obstructive pulmonary disease.	2001-05	11371395
Lack of effect of mossy fiber-released zinc on granule cell GABA(A) receptors in the pilocarpine model of epilepsy.	2001-05	11353010
Diurnal variation in pilocarpine-induced generalized tonic-clonic seizure activity.	2001-05	11325576
Exploring the potential for subtype-selective muscarinic agonists in glaucoma.	2001-04-27	11392632
Neostriatal muscarinic receptor subtypes involved in the generation of tremulous jaw movements in rodents implications for cholinergic involvement in parkinsonism.	2001-04-27	11392629
Alteration of cardiovascular and neuronal function in M1 knockout mice.	2001-04-27	11392617
Adenosine A2A receptor knockout mice are partially protected against drug-induced catalepsy.	2001-04-17	11303773
Initiation of network bursts by Ca2+-dependent intrinsic bursting in the rat pilocarpine model of temporal lobe epilepsy.	2001-04-01	11283235
A new medication for treatment of dry mouth in Sjögren's syndrome.	2001-04	11404944
Immediate diode laser peripheral iridoplasty as treatment of acute attack of primary angle closure glaucoma: a preliminary study.	2001-04	11316102
2-chloro-N(6)-cyclopentyladenosine-elicited attenuation of evoked glutamate release is not sufficient to give complete protection against pilocarpine-induced seizures in rats.	2001-04	11311893
Alkaline phosphatase activity in whitefly salivary glands and saliva.	2001-04	11304750
Impaired neurotransmitter release from lacrimal and salivary gland nerves of a murine model of Sjögren's syndrome.	2001-04	11274068
Stress response to surgical procedures in the submandibular region and its influence on salivary secretion in mice.	2001-04	11269873
Lithium does not synergize the peripheral action of cholinomimetics as seen in the central nervous system.	2001-03-23	11324716
In vivo evaluation of submicron emulsions with pilocarpine: the effect of pH and chemical form of the drug.	2001-03-20	11253934
Normal spatial memory following postseizure treatment with ketamine: selective damage attenuates memory deficits in brain-damaged rodents.	2001-03	11328682
Cocaine abuse, generalized myasthenia, complete external ophthalmoplegia, and pseudotonic pupil.	2001-03	11262695
Brain-derived neurotrophic factor superinduction parallels anti-epileptic--neuroprotective treatment in the pilocarpine epilepsy model.	2001-03	11259499
Do recurrent febrile convulsions decrease the threshold for pilocarpine-induced seizures? Effects of nitric oxide.	2001-02-28	11248357
Beta-adrenergic blocker therapy and the trabecular meshwork.	2001-02	11372544
Randomized double blind, placebo-controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia.	2001-02	11336078
Brief successive temporal observational sampling as a possible indicator of daily overt seizure activity in epileptic rats.	2001-02	11322611
The acute effect of pilocarpine on pulsatile ocular blood flow in ocular hypertension.	2001-02	11318298
Twenty-four hour intraocular pressure reduction with latanoprost compared with pilocarpine as third-line therapy in exfoliation glaucoma.	2001-02	11318297
Normalization of spatial learning despite brain damage in rats receiving ketamine after seizure-induction: evidence for the neuromatrix.	2001-02	11293016
[Dry mouth].	2001-01-31	11252939
Protection by selenium of lead-acetate-induced alterations on rat submandibular gland function.	2001-01	11339622
[The effect of physiological and extreme irritants on zinc metabolism in pancreatic islets and hippocampus cells].	2001	11392117
Synchronized feeding as a "conditioned stimulus" for overt seizures in chronically (limbic) epileptic rats: a model for "psychogenic seizures" with complex partial epilepsy.	2001	11264918
Norepinephrine in treatment of ocular hypertension and glaucoma.	1975-03	1138682

Patents

Sample Use Guides

In Vivo Use Guide

Ophthalmic solution: Instill one drop in the eye(s) up to four times daily. Oral formulation: the recommended dose is 5 mg taken three times a day (Head and Neck Cancer Patients) or 5 mg taken four times a day (Sjogren's Syndrome Patients).

Route of Administration: Other

In Vitro Use Guide

Rat submandibular gland cells were treated wth 100 uM pilocarpine. The drug elicited a small and sustained increase in [Ca2+]i, indicating that pilocarpine acts as a partial agonist for mAChR-mediated Ca2+ responses.

Name

Type

Language

Pilocarpine

Common Name

English

OCUSERT PILO

Preferred Name

English

PILOCARPINUM [HPUS]

Common Name

English

PILOCARPOL

Common Name

English

2(3H)-FURANONE, 3-ETHYLDIHYDRO-4-((1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-, (3S-CIS)-

Systematic Name

English

PILOCARPINE [USP MONOGRAPH]

Common Name

English

PILOCARPINE [MI]

Common Name

English

Pilocarpine [WHO-DD]

Common Name

English

PILOCARPINE [MART.]

Common Name

English

SPERSACARPINE

Common Name

English

OCUCARPINE

Common Name

English

PILOCARPINE [VANDF]

Common Name

English

PILOCARPINE [HSDB]

Common Name

English

PILOCARPINE [USP-RS]

Common Name

English

PILOCARPINE [ORANGE BOOK]

Common Name

English

PILOCARPINE [JAN]

Common Name

English

SYNCARPINE

Common Name

English

PILOKARPIN

Common Name

English

Classification Tree Code System Code

WHO-VATC

QN07AX01